Literature DB >> 17064989

Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene.

Soo Jin Yoo1, Chan Jeoung Park, Seongsoo Jang, Eul-Ju Seo, Kyoo-Hyung Lee, Hyun Sook Chi.   

Abstract

Alterations of the FLT3 gene, in the form of internal tandem duplications (ITD) and D835 point mutations, occur frequently in acute promyelocytic leukemia (APL). We therefore evaluated the frequency and clinical relevance of FLT3 aberrations in a series of Korean APL patients. We assayed FLT3 ITD and D835 mutation status in 75 newly diagnosed APL patients and we correlated the presence of these mutations with clinical parameters and outcomes. Of the 75 patients, fifteen (20.0%) carried FLT3 mutations, nine (12.0%) with FLT3 ITD, seven (9.3%) with D835 mutations and one with both types. Patients presenting with higher leukocyte counts (>10 x 10(9)/L) had a significantly higher frequency of FLT3 ITD (P = 0.030). There was no association between FLT3 aberrations and other clinicohematologic features including age, gender, M3 variant morphology and PML/RARalpha subtype. Death at presentation before induction chemotherapy was significantly more frequent in patients with ITD than in those without ITD (33.3% vs. 4.5%, P = 0.020), but was not significantly related to the presence of D835 mutations (28.6% vs. 5.9%, P = 0.094). Both ITD and D835 mutations were associated with shortened event-free survival (P = 0.048 and P = 0.029, respectively), but there was no correlation between disease-free survival among the 61 patients who achieved complete remission and the presence of FLT3 mutations (P = 0.543 for ITD and P = 0.277 for D835). FLT3 mutations were less frequent in Korean APL patients than in Western APL patients. In Korean patients, however, FLT3 mutations were associated with higher leukemic burdens and early deaths before remission resulting in inferior prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064989     DOI: 10.1080/10428190600687927

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.

Authors:  Harry Iland; Ken Bradstock; John Seymour; Mark Hertzberg; Andrew Grigg; Kerry Taylor; John Catalano; Paul Cannell; Noemi Horvath; Sandra Deveridge; Peter Browett; Tim Brighton; Li Chong; Francisca Springall; Juliet Ayling; Alberto Catalano; Shane Supple; Marnie Collins; Juliana Di Iulio; John Reynolds
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

2.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.

Authors:  Matthew A Kutny; Barry K Moser; Kristina Laumann; James H Feusner; Alan Gamis; John Gregory; Richard A Larson; Bayard L Powell; Wendy Stock; Cheryl L Willman; William G Woods; Soheil Meshinchi
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

3.  Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations.

Authors:  Harshabad Singh; Lillian Werner; Daniel Deangelo; Karen Ballen; Philip Amrein; Martha Wadleigh; Donna Neuberg; Edward Fox; Richard Stone; Eyal Attar
Journal:  Am J Hematol       Date:  2010-12       Impact factor: 10.047

4.  Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy.

Authors:  Eva Barragán; Pau Montesinos; Mireia Camos; Marcos González; Maria J Calasanz; José Román-Gómez; Maria T Gómez-Casares; Rosa Ayala; Javier López; Óscar Fuster; Dolors Colomer; Carmen Chillón; María J Larrayoz; Pedro Sánchez-Godoy; José González-Campos; Félix Manso; Maria L Amador; Edo Vellenga; Bob Lowenberg; Miguel A Sanz
Journal:  Haematologica       Date:  2011-06-17       Impact factor: 9.941

Review 5.  Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.

Authors:  Margaret L Gulley; Thomas C Shea; Yuri Fedoriw
Journal:  J Mol Diagn       Date:  2009-12-03       Impact factor: 5.568

6.  Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.

Authors:  Xavier Poiré; Barry K Moser; Robert E Gallagher; Kristina Laumann; Clara D Bloomfield; Bayard L Powell; Gregory Koval; Kabir Gulati; Nicholas Holowka; Richard A Larson; Martin S Tallman; Frederick R Appelbaum; Dorie Sher; Cheryl Willman; Elisabeth Paietta; Wendy Stock
Journal:  Leuk Lymphoma       Date:  2014-02-04

7.  Treatment outcome of all-trans retinoic acid/anthracycline combination chemotherapy and the prognostic impact of FLT3/ITD mutation in acute promyelocytic leukemia patients.

Authors:  Seung-Dok Hong; Yeo-Kyeoung Kim; Hee-Nam Kim; Se Ryeon Lee; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Il-Kwon Lee; Myung-Geun Shin; Hyeoung-Joon Kim
Journal:  Korean J Hematol       Date:  2011-03-15

8.  Low frequency and variability of FLT3 mutations in Korean patients with acute myeloid leukemia.

Authors:  Soo-Mee Bang; Jeong Yeal Ahn; Jiyoon Park; Se Hoon Park; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee; Soo Jin Yoo; In Sang Jeon; Yeo-Kyeoung Kim; Hyeoung Joon Kim; Hee-Nam Kim; Il-Kwon Lee; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2008-10       Impact factor: 2.153

Review 9.  The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis.

Authors:  Gledson L Picharski; Diancarlos P Andrade; Ana Luiza M R Fabro; Luana Lenzi; Fernanda S Tonin; Raul C Ribeiro; Bonald C Figueiredo
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.